A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

NCT06514742 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

101

Enrollment

INDUSTRY

Sponsor class

Stopped Early study termination due to insufficient efficacy.

Conditions

Depressive Disorder, Major
Anhedonia

Interventions

DRUG: Aticaprant
OTHER: Placebo

Sponsor

Janssen Research & Development, LLC